MDT

85.37

+4.44%↑

VEEV

216.56

+3.47%↑

A

106.89

+8.08%↑

CHE

586.36

+3.03%↑

HQY

83.19

+9.06%↑

MDT

85.37

+4.44%↑

VEEV

216.56

+3.47%↑

A

106.89

+8.08%↑

CHE

586.36

+3.03%↑

HQY

83.19

+9.06%↑

MDT

85.37

+4.44%↑

VEEV

216.56

+3.47%↑

A

106.89

+8.08%↑

CHE

586.36

+3.03%↑

HQY

83.19

+9.06%↑

MDT

85.37

+4.44%↑

VEEV

216.56

+3.47%↑

A

106.89

+8.08%↑

CHE

586.36

+3.03%↑

HQY

83.19

+9.06%↑

MDT

85.37

+4.44%↑

VEEV

216.56

+3.47%↑

A

106.89

+8.08%↑

CHE

586.36

+3.03%↑

HQY

83.19

+9.06%↑

Search

CureVac NV

Gesloten

2.97 9.59

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.69

Max

3

Belangrijke statistieken

By Trading Economics

Inkomsten

443M

371M

Verkoop

479M

494M

K/W

Sectorgemiddelde

5.078

61.151

EPS

1.5

Winstmarge

75.029

Werknemers

999

EBITDA

441M

375M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+249.06% upside

Dividenden

By Dow Jones

Volgende Winsten

10 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

581M

Vorige openingsprijs

-6.62

Vorige sluitingsprijs

2.97

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

CureVac NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 jul 2024, 09:14 UTC

Acquisities, Fusies, Overnames

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 jul 2024, 14:18 UTC

Acquisities, Fusies, Overnames

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 jul 2024, 09:38 UTC

Marktinformatie

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Peer Vergelijking

Prijswijziging

CureVac NV Prognose

Koersdoel

By TipRanks

249.06% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.25 USD  249.06%

Hoogste 16 USD

Laagste 2.5 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor CureVac NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

3 ratings

1

Buy

1

Hold

1

Sell

Technische score

By Trading Central

2.72 / 2.905Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.